Clinical-stage precision oncology company Enliven Therapeutics Inc. (Nasdaq: ELVN) was bullish in its recent earnings report ...

Edwina Bartholomew has provided a positive update on her health nearly two years after being diagnosed with chronic myeloid ...

Researchers sought to determine whether asciminib would have long-term benefit in patients with newly-diagnosed Philadelphia chromosome-positive chronic phase CML.

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

Exclusive: After the devastating news of a terminal cancer diagnosis, Debbie Rhodes and her husband Randy were delivered a ...

When the Food and Drug Administration approved Gleevec to treat a form of leukemia in 2001, it ushered in a new era in cancer ...

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...